| AGENUS INC. DL-,01 |
| USA |
| Gesundheit |
| US00847G8042 / A403RK |
| AJ8 (Frankfurt) / AGEN (NASDAQ) |
| FRA:AJ8, ETR:AJ8, AJ8:GR, NASDAQ:AGEN |
| - |
| https://agenusbio.com/ |
|
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and the development of therapies designed to activate the immune system against cancer. The company’s current work centers on antibody-based therapeutics, immune check..
>Volltext.. |
| 284.84 Mio. EUR |
| 515.75 Mio. EUR |
| 114.69 Mio. EUR |
| 35.1 Mio. EUR |
| 79.53 Mio. EUR |
| 2.35 EUR |
| 250.81 Mio. EUR |
| 16.2 Mio. EUR |
| -85.14 Mio. EUR |
| 0.08 |
| 34.57% |
| - |
| - |
| - |
| - |
| - |
| AGENUS |
| 17.08.26 |
|
||||
|